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Table 1
Differences in synovial ﬂuid biomarkers in acutely knee injured patients with or without at least one concomitant osteochondral fracture.
Median (25th-75th percentile) P-value; Adjusted for:
Fracture No fracture DBI DBI + age + sex DBI + age + sex + TOI
sGAG mg/ml SF 168.4 (77.6-305.6) 134.5 (75.6-331) 0.65 0.59 0.59
ARGS pmol/ml SF 72.9 (32.2-170.7) 59 (18.1-184.5) 0.42 0.47 0.48
OCL ng/ml SF 34.8 (22.8-50.8) 41.8 (25.7-55.7) 0.33 0.62 0.52
SPARC ng/ml SF 471.3 (322.0-767.0) 407 (139.9-684.9) 0 12 0.061 0.057
OPN ng/ml SF 74.6 (20-160.2) 29.1 (5.9-78.9) 0.11 0.11 0.11
IL 1b pg/ml SF 10.9 (4.4-29.6) 11.5 (4.9-27.8) 0.67 0.54 0.52
IL6 pg/ml SF 3386 (740-14425) 3602.3 (1254-14896) 0.95 1.0 0.99
IL8 pg/ml SF 211.4 (88.9-416.6) 137.5 (66.7-412.6) 0.22 0.22 0.22
TMFa pg/ml SF 9.2 (6.6-12.3) 6.9 (4.6-13.7) 0.036 0.013 0.012
COMP ng/ml SF 29885 (20814-36289) 27801 (20638-46503) 0.73 0.81 0.81
Between groups statistical testing was performed using ANCOVA on the log 10 transformed concentrations (adjusted statistics) The covariatcs; days between the injury and
synovial ﬂuid aspiration (DBI), age at injury, sex and type of injury (TOI: ACL, PCL, patellar dislocation, isolated meniscal tear/s or no signs of Structural intraarticular injury to
soft tissues) were included in the adjusted analysis. The tests were two-tailed with a P-value < 0.05 considered statistically signiﬁcant. Signiﬁcant differences are bolded. The
distribution of knee injuries as assessed by MRI between the two groups were as follows; Fracture/No fracture: ACL: 46/14; PCL: 1/1: patellar dislocation; 10/4, isolated
meniscal tear/s: 4/5; no signs of structural intra-articular injury to soft tissues: 6/7
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EXPLORATORY BIOMARKERANALYSIS REVEALS AGENETIC EPISTATIC
INTERACTION IN INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL1RN)
GENE ASSOCIATED TO CARTILAGE VOLUME GROWTH MEASURED BY
MRI IN RESPONSE TO SPRIFERMIN THERAPY IN PATIENTS WITH
KNEE RADIOGRAPHIC OSTEOARTHRITIS
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Purpose: Osteoarthritis (OA) has recently been recognized as a hetero-
geneous disease with different underlying pathophysiologies, thus
opening new possibilities for personalized / stratiﬁed medicine. We
report an exploratory biomarker analysis performed within the context
of a phase 1 randomized, double blind, placebo-controlled, multicenter,
multiple ascending dose study involving sprifermin (recombinant
human FGF18) administered intra-articularly in patients with primary
knee OA.
Methods: Subjects participating in the “Multicenter Study of rhFGF18 in
Patients With Knee Osteoarthritis Not Requiring Surgery” Phase 1
clinical trial (previously presented, OARSI 2011) and consenting to the
pharmacogenomic study were included in this analysis. The trial was
designed as a randomized, double blind, placebo-controlled, multi-
center study. At baseline, all patients had Kellgren-Lawrence grade 2 or
3. All analyses were performed on the pharmacogenomic Intent-To-
Treat population, corresponding to a subset of the clinical database.
Biomarker analyses focused on the Multiple Ascending Dose cohort
(one injection per week for three weeks per subject; two treatment
cycles). The following treatment arms were available: 10 micrograms
(mcg) (with n¼21 subjects), 30 mcg (n¼34) or 100 mcg (n¼50) and
matched placebo subjects (n¼32). Subjects were followed-up for 52
weeks (trial termination date) with evaluation of their total cartilage
thickness/volume growth, measured by MRI, and WOMAC score
assessed at deﬁned time points. Both candidate (TaqMan) and whole-
genome (Affymetrix 6.0 arrays) SNP proﬁling of blood extracted DNA
from consenting subjects were performed. All SNPs were tested for
statistical association with change in total cartilage thickness / volume
at 52 weeks and WOMAC scores using linear models with Kellgren-
Lawrence grade, gender, age and BMI as adjustment covariables
Results: In the non-stratiﬁed PGx population, a median cartilage
volume growth increase of 146.93 mm3 (p ¼ 0.0157) relative to
placebo was observed in the sprifermin MAD 100 mcg arm. Biomarker
analyses identiﬁed a combination of SNPs, rs9005 and rs315952, both
located on the IL1RN gene that retrospectively identiﬁed a group of
patients where an 217.16 mm3 cartilage volume median increase over
placebo (p ¼ 0.0016) was observed. Furthermore, the cartilage volume
change in placebo subjects across the different genetic groups
suggests that this combination of SNP may also be indicative of
disease severity.Conclusions: These results illustrate how pharmacogenomics
approaches can generate exploratory hypotheses, which need to be
conﬁrmed in adequately designed upcoming clinical trials, and suggest
the potential to develop personalized pharmacologic treatment in OA
patients.126
SOLUBLE MACROPHAGE BIOMARKERS ARE ASSOCIATED WITH
OSTEOARTHRITIS-RELATED KNEE INFLAMMATION
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Purpose: Despite the prevalence, disability, and societal and personal
costs of osteoarthritis (OA), current treatment paradigms are limited to
palliative measures and ultimately joint replacement. One of the many
reasons purported for this lack of progress has been the slow evolution
of the understanding of the complex nature of joint tissue biology, and
the absence of biomarkers to identify disease subsets and monitor
efﬁcacy of interventions. A major recent advance in the understanding
of OA pathology has been the recognition of the role of innate immu-
nity. As part of a chronic maladaptive wound healing response in OA,
synovial macrophage-produced cytokines drive aggrecanases, matrix
metalloproteinases, and other destructive responses. We recently
discovered that the pattern of synovial ﬂuid cytokines in knee OA is
indicative of macrophage-mediated inﬂammasome activation. In a pilot
study of knee OA subjects, using a novel nuclear imaging methodology
known as FolateScan, we conﬁrmed the presence of activated macro-
phages in the majority of symptomatic osteoarthritic knees (66% posi-
tive; n¼25 patients, 50 knees). Activated macrophages in the synovium
and joint capsule were both strongly associated with joint space nar-
rowing, osteophyte severity, and knee symptoms. These data demon-
strate that macrophages play a critical role in OA symptoms and
progression. The goal of this study was to evaluate whether soluble
circulating macrophage-related markers, sCD14 and sCD163, were
associated with the presence of activated macrophages localized to the
knee and severity of radiographic knee OA.
Methods: sCD14 and sCD163 were measured by ELISA in the plasma
and sera, respectively of 25 subjects with knee OA. The severity of joint
space narrowing (JSN) and osteophyte (OST) were scored from ﬁxed
ﬂexion knee radiographs with the aid of a standard radiographic atlas.
FolateScan uptake was scored by an experienced reader (REC) on a 0-3
scale for the synovium and joint capsule from SPECT/CT knee scans.
Models using generalized estimating equations (to account for corre-
lation within knees), or ChiSquare analysis (for the biomarkers in
combination) were performed with adjustment for age, gender, and
body mass index, to evaluate associations of the biomarkers with
FolateScan results and radiographic OA features. P values 0.05 were
considered signiﬁcant.
Results: sCD14 and sCD163 were both signiﬁcantly associated with the
quantity of activated macrophages in knees. sCD14 was most strongly
associated with the presence of activatedmacrophages in the capsule of
the patellofemoral (PF) knee compartment (p¼0.0378); sCD163 was
